TOP TEN perturbations for NM_000414 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000414
Selected probe(set): 201413_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000414 (201413_at) across 5339 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):3.9347181
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):3.528862
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

T-cell isolation study 11 / T-cell isolation study 6

Relative Expression (log2-ratio):-3.1130123
Number of Samples:2 / 2
Experimental T-cell isolation study 11
CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20?C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.
Control T-cell isolation study 6
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.9608784
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 ?g/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):2.8296957
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.6879787
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.6082096
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.5640125
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

IgG; C3bi stimulation study 1 (early) / normal polymorphnuclear leukocyte sample

Relative Expression (log2-ratio):2.4410057
Number of Samples:11 / 10
Experimental IgG; C3bi stimulation study 1 (early)
Polymorphonuclear leukocytes (PMNs) from healthy donors, incubated with IgG- and C3bi-coated latex beads at 37?C in a CO2 incubator for 3h. ATC code:---
Control normal polymorphnuclear leukocyte sample
Polymorphonuclear leukocytes (PMNs) from healthy donors, incubated without IgG- and C3bi-coated latex beads at 37?C in a CO2 incubator for 3h.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.4009066
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.